Idera Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch IDRA and buy or sell other stocks, ETFs, and their options commission-free!

About IDRA

Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the research and development of medications for rare and orphan diseases. 

CEO
John Clayton Taylor
CEOJohn Clayton Taylor
Employees
Employees
Headquarters
Research Triangle Park, North Carolina
HeadquartersResearch Triangle Park, North Carolina
Founded
1989
Founded1989
Employees
Employees

IDRA Key Statistics

Market cap
3.20M
Market cap3.20M
Price-Earnings ratio
-0.07
Price-Earnings ratio-0.07
Dividend yield
Dividend yield
Average volume
44.14K
Average volume44.14K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$16.00
52 Week high$16.00
52 Week low
$0.3601
52 Week low$0.3601

Stock Snapshot

Idera Pharmaceuticals(IDRA) stock is priced at $1.60, giving the company a market capitalization of 3.2M. It carries a P/E multiple of -0.07.

On 2026-04-01, Idera Pharmaceuticals(IDRA) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Idera Pharmaceuticals(IDRA) stock has reached 0, versus its average volume of 44.14K.

The stock's 52-week range extends from a low of $0.36 to a high of $16.00.

The stock's 52-week range extends from a low of $0.36 to a high of $16.00.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.